Nuvalent

NuvalentNUVL

Price

$ 78.1

Market Capitalization

$ 5.04 B

Shares Outstading

64.556 M

Change

$ 0

Percentage Change

0 %

Country

United States 🇺🇸

Industry

Biotechnology

Healthcare

Exchange

NASDAQ Global Select

IPO

2021-07-29

Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and rem

EPS of Nuvalent ( NUVL)

EPS : -1.8499999999999999

Nuvalent has EPS of -1.8499999999999999 .The current price of Nuvalent is $78.1 (0 %).

Earnings Per Share (EPS) is a financial metric that represents the portion of a company's profit allocated to each outstanding share of common stock. It is calculated by dividing the company's net income by the number of outstanding shares. EPS is a key indicator of a company's profitability and is often used by investors to assess a company's financial performance on a per-share basis. Higher EPS generally indicates higher profitability and can influence stock valuation.
EPS of Nuvalent from 2020 to 2024
Year on Year EPS of Nuvalent
EPS
YearEPSChange %
2023-1.85012.8%
2022-1.64030.08%
2021-1.26151.04%
2020-0.835
Market Cap of Magnificent 7

Stock Ticker

Market Cap

Price

Change

Price(30 Days)

Country

$ 3.335 T

$ 135.58

0.00%

$ 0

United States🇺🇸

$ 3.317 T

$ 446.34

0.00%

$ 0

United States🇺🇸

$ 3.286 T

$ 214.29

0.00%

$ 0

United States🇺🇸

$ 2.171 T

$ 176.45

0.00%

$ 0

United States🇺🇸

$ 1.902 T

$ 182.81

0.00%

$ 0

United States🇺🇸

$ 1.787 T

$ 7.38371

0.01%

$ 0

Saudi Arabia🇸🇦

$ 1.267 T

$ 499.49

0.00%

$ 0

United States🇺🇸

NEWSLETTER

MarketStreak weekly Newsletter

Get weekly Stock Market/Crypto News and Jobs updates directly to your inbox.

MarketStreak Research

Research

Latest data-backed business trends, research insights, and industry analyses.

MarketStreak Inc.

TEXAS, USA 🇺🇸

Disclaimer : The content on our website, including hyperlinked sites, associated applications, forums, blogs, and social media accounts, is for general information only and sourced from third-party providers. We offer no warranties regarding the content's accuracy or updatedness. Please note that our content should not be considered financial or legal advice. Always conduct thorough research and consult with a financial advisor before making any decisions. Trading is a high-risk activity that can lead to significant losses, so please seek professional guidance before making any trading decisions. Our content is not meant to be a solicitation or offer.